ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Cuproptosis-related signature for clinical prognosis and immunotherapy sensitivity in hepatocellular carcinoma

Xu, Shaohua; Dong, Kexin; Gao, Ruihuan; Yang, Ying; Zhou, Yidan; Luo, Chunhua; Chen, Wei*; Liu, Song-Mei*武汉大学; 1
Journal of Cancer Research and Clinical Oncology2023-10DOI: 10.1007/s00432-023-05099-x
1被引16阅读
引用收藏
分享

摘要

BackgroundCopper homeostasis imbalance has been implicated in tumor progression, aggressiveness, and treatment response. However, the precise roles of cuproptosis-related genes (CRGs) in hepatocellular carcinoma (HCC) remain poorly understood.MethodsIn this study, we employed a consensus clustering algorithm to identify distinct molecular subtypes. We then performed Kaplan-Meier analysis and univariate Cox regression analysis to identify prognostic differentially expressed genes. The expression of these genes was subsequently validated using qPCR on fresh-frozen tissues obtained from HCC patients. Moreover, leveraging the TCGA-HCC cohort, we constructed a CRGs-related risk prediction model using the LASSO and multivariate Cox regression analysis.ResultsBy analyzing the data, we successfully established a CRGs risk prognostic model for HCC patients, comprising five differential genes (CAD, SGCB, TXNRD1, KDR, and MTND4P20). Cox regression analysis revealed that the CRGs risk score could serve as an independent prognostic factor for overall survival (hazard ratio [HR] = 1.308, 95% confidence interval [CI] = 1.200 - 1.426, P < 0.001). The area under the curve (AUC) values of the CRGs-score for predicting 1-year, 3-year, and 5-year survival rates were 0.785, 0.724, and 0.723, respectively. Notably, the expression levels of immune checkpoints (including PD-1, PD-L1, and CTLA4) significantly differed between the low- and high-risk score groups. Furthermore, the low-risk score group displayed increased sensitivity to sorafenib, cisplatin, cyclopamine, nilotinib, salubrinal, and gemcitabine, whereas the high-risk score group exhibited heightened sensitivity to lapatinib, erlotinib, and gefitinib.ConclusionsOur findings highlight the potential of the CRGs risk score as an independent and promising biomarker for clinical prognosis and immunotherapy sensitivity in HCC patients.

学科与关键词

关键词
CuproptosisHepatocellular carcinomaTumor microenvironmentPrognostic modelChemotherapy sensitivity
相关
加载中…
  • Cuproptosis-related genes score: A predictor for hepatocellular carcinoma prognosis, immunotherapy efficacy, and metabolic reprogramming
    Nie, Guilin; Peng, Dingzhong; Wen, Ningyuan; Wang, Yaoqun; Lu, Jiong*; Li, Bei*Frontiers in Oncology, 2023, 13: 1096351.
  • Prognostic and metabolic characteristics of a novel cuproptosis-related signature in patients with hepatocellular carcinoma
    Qu, Xin; Meng, Ling-cui; Lu, Xi; Chen, Xian; Li, Yong; Zhou, Rui; Zhu, Yan-juan; Luo, Yi-chang; Huang, Jin-tao; Shi, Xiao-liang; Zhang, Hai-Bo*Heliyon, 2024, 10(1): e23686.
  • Identifying a novel cuproptosis-related necroptosis gene subtype-related signature for predicting the prognosis, tumor microenvironment, and immunotherapy of hepatocellular carcinoma
    Shi, Yuanxin; Qiu, Peng; Zhao, Kai; Li, Xiangyu; Feng, Yunxiang; Deng, Zhengdong*; Wang, Jianming*Frontiers in Molecular Biosciences, 2023, 10: 1165243.
查看全部 →

发表信息

论文状态
公开发表
期刊
Journal of Cancer Research and Clinical Oncology
发表日期
2023-10
卷期
第 149 卷, 第 13 期
页码
12249-12263
DOI
10.1007/s00432-023-05099-x
语言
ENGLISH
成果收录
SCIE
资助标注
National Natural Science Foundation of China [81772276]; Hubei Provincial Natural Science Fund for Creative Research Groups [2019CFA018]

作者

  • X

    Xu, Shaohua (第一作者)

    wuhan univ

  • D

    Dong, Kexin

    wuhan univ

查看全部 8 位作者收起作者
  • G

    Gao, Ruihuan

    wuhan univ

  • Y

    Yang, Ying

    wuhan univ

  • Z

    Zhou, Yidan

    wuhan univ

  • L

    Luo, Chunhua

    1 · three gorges univ

  • C

    Chen, Wei (通讯)

    wuhan univ

  • L

    Liu, Song-Mei (通讯)

    wuhan univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417